Sansheng pharmaceutical's recombinant humanized anti-il-17a monoclonal antibody was approved by the clinical trial of the State Food and drug administration

August 2, 2019 / Meitong news agency / -- China's leading biopharmaceutical company Sansheng Pharmaceutical (01530 HK) announced today that the company's self-developed recombinant humanized anti interleukin-17A monoclonal antibody injection (608) has submitted the clinical trial application to the State Drug Administration for approval At present, Sansheng pharmaceutical is actively carrying out the preparation of clinical trials of the product The indication of 608 was severe plaque psoriasis Psoriasis is a common immune related chronic recurrent inflammatory skin disease [1], which is a chronic inflammatory proliferative skin disease mainly mediated by abnormal cellular immunity under the interaction of polygenetic inheritance and environment [2] According to the epidemiological survey, the prevalence of psoriasis in China was 0.123% in 1984, and 0.47% in 2008, which reflected the rising trend of the prevalence of psoriasis in China [3] In recent years, the harm of psoriasis has been paid more and more attention by the medical community Studies have shown that nearly 30% of patients with psoriasis may develop psoriatic arthritis (PSA) The joint involvement of PSA can cause pain, stiffness and other uncomfortable symptoms Some patients may even have irreversible joint damage, resulting in joint deformation and disability Psoriasis is often accompanied by other diseases, such as diabetes, heart disease and depression [4], which seriously affect the physical and mental health and quality of life of patients This approved 608 product is expected to bring more treatment options for psoriasis patients Dr Lou Jing, chairman and chief executive officer of Sansheng pharmaceutical commented: "we are very pleased to see that the clinical trial application of 608 has been officially approved by the State Drug Administration, and we are looking forward to accelerating the clinical trial process of recombinant human anti IL-17A monoclonal antibody injection in China Sansheng pharmaceutical will continue to explore and develop safer and more effective therapeutic biological agents to provide patients with new treatment options of high quality, high efficiency and affordability " References: [1] psoriasis group, dermatology and Venereology branch, Chinese Medical Association Consensus of Chinese experts on psoriasis treatment (2014) Chinese Journal of Dermatology 2014; 47:213-15 [2] Wang Liwei, Yang Ying, Cui pangen Efficacy and safety of anti IL-17 biological agents in the treatment of psoriasis International Journal of Dermatology and Venereology 2016; 42:149-152 [3] Zhang Jianzhong Epidemiology and risk factors of psoriasis Journal of clinical practice of practical hospital 2013; 10:4-6 [4] Farley e, mentor A psoriasis: comorbidities and associations G it dermotol venereol 2011; 146 (1): 9-15 about 608608 is a recombinant humanized monoclonal antibody against interleukin-17A, which is expressed in Chinese hamster ovary cells (CHO) by DNA recombination technology and used for the treatment of moderate and severe plaque psoriasis About Sansheng pharmaceutical, Sansheng pharmaceutical is a comprehensive biotechnology company, with the market leading biopharmaceutical business, covering cancer, autoimmune diseases, kidney disease, metabolic diseases, skin diseases and other treatment fields Sansheng pharmaceutical is committed to building an innovative product pipeline, and there are more than 30 candidate products under development Sansheng pharmaceutical has the ability to produce monoclonal antibody, recombinant protein and chemical synthetic molecular products It has R & D and production centers in Shenyang, Shanghai, Hangzhou, Shenzhen and Como, Italy Please visit